Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Conditions:   Non-Small Cell Lung Cancer;   RET Driver Mutation;   BRAF V600 Mutation;   Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation;   MET Amplification;   MET Exon 14 Skipping Mutation Interventions:   Biological: Toripalimab;   Drug: Nab paclitaxel;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   Guangdong Provincial People's Hospital;   Shanghai Junshi Bioscience Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials